# Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj

> **NCT02532569** · PHASE4 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 94 (actual)

## Conditions studied

- Japanese Encephalitis

## Interventions

- **BIOLOGICAL:** Japanese encephalitis vaccine

## Key facts

- **NCT ID:** NCT02532569
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2017-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02532569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02532569, "Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02532569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*